A class of 9-amino-3,4-dihydroacridine-1(2H)-one compounds and their applications

By designing 9-amino-3,4-dihydroacridine-1(2H)-one compounds, the problem of existing anti-inflammatory drugs to the gastrointestinal tract and renal toxicity has been solved, and chronic inflammation and novel coronaviruses have been achieved. Effective treatment of inflammation, showing excellent anti-inflammatory effects and safety.

CN115947686BActive Publication Date: 2024-11-12ZHEJIANG UNIV OF TECH
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202211546199.9
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-12-05
Publication Date
2024-11-12
Estimated Expiration
2042-12-05

AI Technical Summary

Technical Problem

Existing anti-inflammatory drugs are significantly toxic to the gastrointestinal tract and kidneys, making it difficult to develop safe and efficient new anti-inflammatory drugs to treat chronic inflammation and inflammation caused by the novel coronavirus.

Method used

A class of 9-amino-3,4-dihydroacridine-1(2H)-one compounds were designed, catalyzed by 1,3-cyclohexanedione and 2-aminobenzonitrile derivatives under toluenesulfonic acid The dehydration and condensation reaction was carried out, and then the cyclization reaction was carried out under the action of CuCl and K2CO3 to produce a compound with an anti-inflammatory effect.

Benefits of technology

The compound showed excellent anti-inflammatory effect, was able to effectively inhibit the expression of TNF-α, was used to treat inflammation-related diseases, and was pharmaceutically safe and efficient.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN115947686B_ABST
    Figure CN115947686B_ABST
Patent Text Reader

Abstract

The present invention discloses a class of 9-amino-3,4-dihydroacridine-1(2H)-ketone compounds and applications thereof, wherein the 9-amino-3,4-dihydroacridine-1(2H)-ketone compounds have the following general structural formula: #imgabs0# wherein R is selected from H, halogen, C1-C3 alkyl, C1-C3 alkoxy, carboxyl, methyl ester group, ethyl ester group or aromatic heterocycle. The 9-amino-3,4-dihydroacridine-1(2H)-ketone compounds designed and synthesized by the present invention are a class of novel anti-inflammatory compounds, which can be used for the treatment of inflammation-related diseases. The embodiments of the present invention are verified to have excellent anti-inflammatory effects through experiments, which are of great significance for exploring the mechanism of inflammatory reactions and developing safe and efficient novel anti-inflammatory drugs.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to a class of 9-amino-3,4-dihydroacridine-1(2H)-one compounds and applications thereof. Background Art

[0002] Inflammation is a defense response of the body to stimulation, manifested as redness, swelling, heat, pain and dysfunction, etc. It is one of the most important defense responses of the human body to tissue damage or microbial invasion. Under normal physiological conditions, the immune response caused by inflammation is beneficial to the host, but excessive inflammation, especially chronic inflammation, can lead to immune system abnormalities. Common inflammations such as chronic hepatitis B, gastrointestinal inflammation, and osteoarthritis have a high incidence rate. As an infectious pneumonia, the new coronavirus has the characteristics of fast transmission speed and strong infection ability. Various types of inflammation endanger human health. At present, the commonly used anti-inflammatory drugs in clinical practice are mainly non-steroidal anti-inflammatory drugs, but common non-steroidal anti-inflammatory drugs can cause obvious toxicity to the gastrointestinal tract and kidneys. Therefore, it is of great significance to explore the mechanism of inflammatory response and develop safe and efficient new anti-inflammatory drugs. Summary of the invention

[0003] In view of the above technical problems existing in the prior art, the object of the present invention is to provide a class of 9-amino-3,4-dihydroacridine-1(2H)-one compounds and applications thereof.

[0004] The technical solution adopted by the present invention is as follows:

[0005] The 9-amino-3,4-dihydroacridine-1(2H)-one compounds are characterized in that the compounds have the following general structural formula:

[0006]

[0007] Wherein R is selected from H, halogen, C1-C3 alkyl, C1-C3 alkoxy, carboxyl, methyl ester, ethyl ester or aromatic heterocycle.

[0008] Furthermore, the 9-amino-3,4-dihydroacridin-1(2H)-one compound is specifically selected from the following:

[0009]

[0010] The preparation method of the 9-amino-3,4-dihydroacridine-1(2H)-one compounds, the synthesis route of compounds 4a-4k is shown in the following reaction formula. 1,3-cyclohexanedione 1 and 2-aminobenzonitrile derivatives 2a-2j are used as raw materials, p-toluenesulfonic acid is used as a catalyst, and a dehydration condensation reaction is carried out under toluene reflux to obtain intermediates 3a-3j, and 3a-3j are subjected to a cyclization reaction under the action of CuCl and K2CO3 under tetrahydrofuran reflux conditions to obtain 9-amino-3,4-dihydroacridine-1(2H)-one derivatives 4a-4j.

[0011]

[0012] The invention relates to the use of the 9-amino-3,4-dihydroacridine-1(2H)-one compounds and pharmaceutically acceptable salts thereof in the preparation of anti-inflammatory drugs.

[0013] By adopting the above technology, compared with the prior art, the beneficial effects of the present invention are as follows:

[0014] The 9-amino-3,4-dihydroacridine-1(2H)-one compounds designed and synthesized by the present invention are a new type of anti-inflammatory compounds and can be used to treat inflammation-related diseases. The present invention has excellent anti-inflammatory effects as verified by experiments. DETAILED DESCRIPTION

[0015] The present invention will be further described below in conjunction with specific embodiments, but the protection scope of the present invention is not limited thereto.

[0016] 1. Preparation of intermediates and target compounds:

[0017] Example 1: 9-amino-3,4-dihydroacridin-1(2H)-one (4a)

[0018]

[0019] Add 4.23mmol 2-aminobenzonitrile (4-2a), 12.69mmol cyclohexane-1,3-dione, 8.46mmol p-toluenesulfonic acid hydrate and 20mL toluene to the reaction flask, and reflux for 6h. After the reaction, pour out the upper toluene solution, dilute with water, adjust the reaction solution to alkalinity with 10% sodium hydroxide solution, add dichloromethane to the reaction flask for extraction (20mL×3), combine the organic phases, wash the organic phases with saturated brine (20mL×3), dry over anhydrous sodium sulfate, filter, and concentrate the filtrate under reduced pressure to obtain intermediate 4-3a, which is directly used in the next step. Add 4.71mmol intermediate 4-3a, 1.70mmol anhydrous potassium carbonate, 0.28mmol cuprous chloride and 20mL tetrahydrofuran to the reaction flask, and reflux for 6h. After the reaction, the mixture was diluted with water and extracted with ethyl acetate (20 mL×3). The organic phases were combined, washed with saturated brine (20 mL×3), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (PE:EA:MeOH:TEA=20:10:1:1, v / v / v / v) to obtain 150 mg of a yellow solid with a yield of 16.7%. 1 H NMR(500MHz,DMSO-d6)δ10.02(s,1H),8.41(s,1H),8.34(d,J=8.3Hz,1H),7.72–7.68(m,2H) ,7.47–7.39(m,1H),2.98(t,2H),2.65(t,J=6.4Hz,2H),2.06–1.98(m,2H).ESI-MS:m / z[M+H] + 213.

[0020] Example 2: 9-amino-5-bromo-3,4-dihydroacridin-1(2H)-one (4b)

[0021]

[0022] The synthesis steps of 9-amino-5-bromo-3,4-dihydroacridin-1(2H)-one are the same as those of 4a, except that compound 4-2a is replaced with an equal molar amount of compound 4-2b (the substituent R in compound 4-2b refers to the substituent R in target compound 4b). The reaction yields a yellow solid in a yield of 17.7%. 1HNMR(500MHz,DMSO-d6)δ10.07(s,1H),8.53(s,1H),8.37(dd,J=8.4,1.3Hz,1H),8.07(dd,J=7.5,1.1Hz,1 H),7.36–7.31(m,1H),3.02(dd,J=6.9,5.4Hz,2H),2.70–2.63(m,2H),2.08–2.00(m,2H).ESI-MS:m / z[M+H] + 291.

[0023] Example 3: 9-amino-6-bromo-3,4-dihydroacridin-1(2H)-one (4c)

[0024]

[0025] The synthesis steps of 9-amino-6-bromo-3,4-dihydroacridin-1(2H)-one are the same as those of 4a, except that compound 4-2a is replaced with an equal molar amount of compound 4-2c (the substituent R in compound 4-2c refers to the substituent R in target compound 4c). The reaction yields a yellow solid in a yield of 41.9%. 1 HNMR(500MHz,DMSO-d6)δ10.03(s,1H),8.50(s,1H),8.29(d,J=8.9Hz,1H),7.87(d,J=2.0Hz,1H),7 .59(dd,J=8.9,2.1Hz,1H),2.97(t,2H),2.64(t,J=6.4Hz,2H),2.06–1.97(m,2H).ESI-MS:m / z[M+H] + 291.

[0026] Example 4: 9-amino-7-bromo-3,4-dihydroacridin-1(2H)-one (4d)

[0027]

[0028] The synthesis steps of 9-amino-7-bromo-3,4-dihydroacridin-1(2H)-one are the same as those of 4a, except that compound 4-2a is replaced with an equal molar amount of compound 4-2d (the substituent R in compound 4-2d refers to the substituent R in target compound 4d). The reaction affords a yellow solid in a yield of 41.3%. 1HNMR(500MHz,DMSO-d6)δ10.02(s,1H),8.64(d,J=2.2Hz,1H),8.51(s,1H),7.82(dd,J=8.8,2.2Hz,1H),7. 63(d,J=8.8Hz,1H),2.97(t,J=6.2Hz,2H),2.65(t,J=6.4Hz,2H),2.02(p,J=6.4Hz,2H).ESI-MS:m / z[M+H] + 291.

[0029] Example 5: 9-amino-8-bromo-3,4-dihydroacridin-1(2H)-one (4e)

[0030]

[0031] The synthesis steps of 9-amino-8-bromo-3,4-dihydroacridin-1(2H)-one are the same as those of 4a, except that compound 4-2a is replaced with an equal molar amount of compound 4-2e (the substituent R in compound 4-2e refers to the substituent R in target compound 4e). The reaction affords a yellow solid in a yield of 46.0%. 1 HNMR(500MHz,DMSO-d6)δ10.02(s,1H),8.41(s,1H),8.34(d,J=8.3Hz,1H),7.72–7. 68(m,2H),2.98(t,2H),2.65(t,J=6.4Hz,2H),2.05–2.00(m,2H).ESI-MS:m / z[M+H] + 291.

[0032] Example 6: 9-amino-5-methoxy-3,4-dihydroacridin-1(2H)-one (4f)

[0033]

[0034] The synthesis steps of 9-amino-5-methoxy-3,4-dihydroacridin-1(2H)-one are the same as those of 4a, except that 4-2a is replaced with an equal molar amount of compound 4-2f (the substituent R in compound 4-2f refers to the substituent R in target compound 4f), and the reaction gives a light yellow solid with a yield of 27.9%. 1HNMR(500MHz,DMSO-d6)δ9.94(s,1H),8.26(s,1H),7.85(dd,J=8.5,1.1Hz,1H),7.35(t,J=8.1Hz,1H),7.19(dd,J =7.9,1.1Hz,1H),3.90(s,3H),2.97(t,J=6.2Hz,2H),2.64(t,J=6.4Hz,2H),2.07–1.96(m,2H).ESI-MS:m / z[M+H] + 243.

[0035] Example 7: 9-amino-6-methoxy-3,4-dihydroacridin-1(2H)-one (4 g)

[0036]

[0037] The synthesis steps of 9-amino-6-methoxy-3,4-dihydroacridin-1(2H)-one are the same as those of 4a, except that 4-2a is replaced with an equal molar amount of compound 4-2g (the substituent R in compound 4-2g refers to the substituent R in target compound 4g), and the reaction gives a light yellow solid with a yield of 17.8%. 1 HNMR(500MHz,DMSO-d6)δ9.91(s,1H),8.24(s,1H),8.22(s,1H),7.12(d,J=2.6Hz,1H),7.05(dd,J=9 .1,2.6Hz,1H),3.89(s,3H),2.94(t,2H),2.61(t,J=6.4Hz,2H),2.03–1.99(m,2H).ESI-MS:m / z[M+H] + 243.

[0038] Example 8: 9-amino-7-methoxy-3,4-dihydroacridin-1(2H)-one (4h)

[0039]

[0040] The synthesis steps of 9-amino-7-methoxy-3,4-dihydroacridin-1(2H)-one are the same as those of 4a, except that 4-2a is replaced with an equal molar amount of compound 4-2h (the substituent R in compound 4-2h refers to the substituent R in target compound 4h). The reaction yields a light yellow solid in a yield of 45.9%. 1HNMR(500MHz,DMSO-d6)δ9.96(s,1H),8.26(s,1H),7.73(d,J=2.7Hz,1H),7.63(d,J=9.0Hz,1H),7.34(dd ,J=9.0,2.7Hz,1H),3.89(s,3H),2.94(t,2H),2.64(t,J=6.4Hz,2H),2.05–1.94(m,2H).ESI-MS:m / z[M+H] + 243.

[0041] Example 9: 9-amino-8-methoxy-3,4-dihydroacridin-1(2H)-one (4i)

[0042]

[0043] The synthesis steps of 9-amino-8-methoxy-3,4-dihydroacridin-1(2H)-one are the same as those of 4a, except that 4-2a is replaced with an equal molar amount of compound 4-2i (the substituent R in compound 4-2i refers to the substituent R in target compound 4i), and the reaction gives a light yellow solid with a yield of 15.5%. 1 HNMR(500MHz,DMSO-d6)δ10.46(s,1H),8.67(s,1H),7.59(t,J=8.2Hz,1H),7.25(dd,J=8.3,0.9Hz,1H ),6.91(dd,1H),3.99(s,3H),2.91(t,2H),2.62(t,J=6.4Hz,2H),2.02–1.96(m,2H).ESI-MS:m / z[M+H] + 243.

[0044] Example 10: 9-amino-8-oxo-5,6,7,8-tetrahydroacridine-2-carboxylic acid methyl ester (4j)

[0045]

[0046] The synthesis steps of 9-amino-8-oxo-5,6,7,8-tetrahydroacridine-2-carboxylic acid methyl ester are the same as those of 4a, except that 4-2a is replaced with an equal molar amount of compound 4-2j (the substituent R in compound 4-2j refers to the substituent R in target compound 4j), and the reaction gives a white solid with a yield of 22.1%. 1HNMR(500MHz,DMSO-d6)δ10.13(s,1H),9.06(d,J=1.9Hz,1H),8.87(s,1H),8.15(dd,J=8.7,1.8Hz,1H),7.75(d ,J=8.7Hz,1H),3.92(s,3H),3.00(t,J=6.2Hz,2H),2.66(t,J=6.4Hz,2H),2.07–2.00(m,2H).ESI-MS:m / z[M+H] + 271.

[0047] 2. Test of TNF-α inhibitory activity

[0048] After resuspending the RAW264.7 cells in a large dish, add 1×10 5 The cells were inoculated into a 96-well plate at a density of 100 ng / mL and cultured in a cell culture incubator at 37°C. When the cell density grew to 50% to 60%, the test compound was diluted with 1% fetal bovine serum DMEM medium and pre-administered with the test compound (the final concentration of the test compound was 10 μM), and an equal amount of 1% fetal bovine serum DMEM medium was added as a blank control, and the cells were returned to the incubator for culture for 12 hours. Then, LPS was added to each well at a final concentration of 100 ng / mL. After culturing in a cell culture incubator for 3 hours, 60 μL of cell supernatant was aspirated and the expression of TNF-α in the supernatant was determined by ELISA. The test results of compounds 4a to 4j are shown in Table 1:

[0049] Table 1 Inhibitory activity of compounds 4a-4j on TNF-α

[0050]

[0051] The contents described in this specification are merely an enumeration of implementation forms of the inventive concept, and the protection scope of the present invention should not be regarded as being limited to the specific forms described in the embodiments.

Claims

1. Use of a class of 9-amino-3,4-dihydroacridine-1(2H)-one compounds and pharmaceutically acceptable salts thereof in the preparation of anti-inflammatory drugs, characterized in that This class of compounds has the following general structural formula: wherein R is selected from 8-Br.